Allogene Therapeutics (ALLO) Enterprise Value (2019 - 2025)
Allogene Therapeutics' Enterprise Value history spans 7 years, with the latest figure at -$252.2 million for Q3 2025.
- For Q3 2025, Enterprise Value rose 13.5% year-over-year to -$252.2 million; the TTM value through Sep 2025 reached -$252.2 million, up 13.5%, while the annual FY2024 figure was -$292.5 million, 34.82% up from the prior year.
- Enterprise Value for Q3 2025 was -$252.2 million at Allogene Therapeutics, up from -$271.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$252.2 million in Q3 2025 and bottomed at -$639.3 million in Q1 2021.
- The 5-year median for Enterprise Value is -$448.7 million (2023), against an average of -$424.0 million.
- The largest YoY upside for Enterprise Value was 49.08% in 2021 against a maximum downside of 29.7% in 2021.
- A 5-year view of Enterprise Value shows it stood at -$399.9 million in 2021, then fell by 16.84% to -$467.2 million in 2022, then rose by 3.96% to -$448.7 million in 2023, then surged by 34.82% to -$292.5 million in 2024, then grew by 13.77% to -$252.2 million in 2025.
- Per Business Quant, the three most recent readings for ALLO's Enterprise Value are -$252.2 million (Q3 2025), -$271.6 million (Q2 2025), and -$280.0 million (Q1 2025).